Keel
Healing & Recovery

TB-500

TB-500 is a synthetic peptide built from a small, specific piece of a larger protein called Thymosin Beta-4, one that the body uses to help cells move and reorganize during tissue repair. Researchers have studied this fragment specifically because it appears to retain much of the parent protein's activity in a smaller, more workable package.

Sequence
7 amino acids (the actin-binding region of Thymosin Beta-4)
Half-Life
Not well established; published data is limited
Format
Lyophilized powder

What Is TB-500?

TB-500 is a synthetic version of a specific seven-amino-acid segment found within Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein present throughout the body. That segment is known as the actin-binding motif, the part of the protein responsible for interacting with actin, a building-block protein that gives cells their shape and lets them move.

Researchers built TB-500 around this specific fragment after studies found that it retained meaningful activity from the full-length protein, making it a smaller, more practical tool for research than the complete 43-amino-acid molecule. While the fragment has been directly tested in several studies, the much larger body of Thymosin Beta-4 research, including its furthest-along human trials, has used the full-length protein rather than this shortened piece specifically.

What TB-500 Is Being Researched For

  • Cell Migration and Tissue Repair

    The foundational research on this actin-binding fragment found it promoted dermal wound repair in diabetic and aged mice, conditions where healing is typically delayed, matching results seen with the full-length protein in the same study.[1]

  • Blood Vessel Formation

    Research isolating this same fragment found it was sufficient on its own to drive angiogenic activity, meaning the formation of new blood vessels, at a level comparable to the complete Thymosin Beta-4 protein in cell and tissue models.[2]

  • Wound Healing

    Broader foundational research on Thymosin Beta-4, the parent protein this fragment is drawn from, established its role in accelerating wound healing across multiple animal models, providing the research context this fragment was later tested against.[3]

How TB-500 Works

  • Interacting With Actin

    Research points to TB-500's core function coming from its ability to bind actin, temporarily holding it in a form that isn't yet built into the cell's structural framework. This actin-binding activity is what allows cells to reorganize quickly and move toward an area that needs repair.[2]

  • Driving Blood Vessel Formation

    Research points to this same actin-binding activity being what drives new blood vessel formation, since studies isolating just this fragment found it retained the angiogenic activity of the full-length protein, identifying it as the specific region responsible for that effect.[2]

  • Supporting Cell Movement During Healing

    Research points to this fragment promoting the kind of cell movement and reorganization needed for wound repair, with studies in diabetic and aged mice, both models of delayed healing, finding it accelerated repair in a way that matched the full-length protein's activity.[1]

Reconstitution and Handling

TB-500 is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

TB-500 is built around the specific piece of Thymosin Beta-4 responsible for its actin-binding activity, and the research directly testing this fragment, rather than just the full-length protein, has found it retains meaningful activity in both wound repair and blood vessel formation models. That said, this fragment's own research base is considerably smaller than the parent protein's, and no human trial data exists for it specifically. Treat findings on the full-length protein as related context rather than direct evidence for this shortened version.

Clinical Overview

Evidence Summary

  • Animal

    The synthetic actin-binding fragment corresponding to TB-500 promoted dermal wound repair in db/db diabetic and aged mice, models of delayed healing, matching results seen with full-length Thymosin Beta-4 in the same study.[1]

  • In vitro

    The isolated actin-binding fragment was sufficient to drive angiogenic activity comparable to full-length Thymosin Beta-4 in cell and tissue models.[2]

  • Animal

    Broader research on the parent protein Thymosin Beta-4 established a role in accelerating wound healing across multiple animal models, providing the context this fragment was tested against; that work is related rather than direct evidence for the fragment.[3][4]

  • In vitro

    The mechanistic basis is attributed to actin sequestration, which supports the cell migration and reorganization required for tissue repair.[2][4]

Pharmacokinetics

  • Route

    Studied and used in research as a subcutaneous or intramuscular injection after reconstitution from lyophilized powder.

  • Half-Life

    No validated pharmacokinetic half-life for the TB-500 fragment has been published; the parameter is not well established.

  • Human Pharmacokinetics

    No peer-reviewed human pharmacokinetic data exist for this specific seven-amino-acid fragment; human trial data that exist pertain to the full-length Thymosin Beta-4 protein and do not directly transfer.[4]

  • Regulatory Status

    TB-500 is not an FDA-approved drug; it is sold as a research chemical, and thymosin beta-4 and related fragments are prohibited in sport under the WADA prohibited list.[5]

Contraindications and Interactions

  • Not FDA-approved for any indication; no published human dosing, purity, or safety standards exist, so all human use is investigational.
  • No published human data address safety in pregnancy or lactation.
  • The fragment promotes angiogenesis in preclinical models, a property that could theoretically support tumor vascularization; no human data address use in patients with malignancy.[2]
  • Prohibited in competitive sport under the World Anti-Doping Agency prohibited list, so athletes risk sanctions.[5]
  • No published human interaction studies exist.
  • Research-chemical sourcing is not subject to regulatory oversight, a general concern with unapproved compounds.

Monitoring Parameters

  • No validated clinical monitoring protocol has been published; any use is experimental.
  • Clinicians who encounter disclosed use commonly note injection-site reactions and any systemic symptoms.
  • Given the theoretical pro-angiogenic effects reported preclinically, age-appropriate cancer screening is a common general-practice consideration.[2]
  • Documenting disclosed use and reviewing concomitant medications reflects general practice given the absence of human interaction data.
  • Athletes should be aware that use is prohibited in competition under the WADA prohibited list.[5]

Reported Adverse Events

  • No published human adverse-event data characterize the safety profile of the fragment in people.[4]
  • Injection-site reactions are plausible with parenteral use, as with other injectable peptides; no published human data confirm this for TB-500.

Frequently Asked Questions

What Is TB-500 Derived From?

It's a synthetic version of a small, specific segment of Thymosin Beta-4, a larger protein the body uses in cell movement and tissue repair.

Is TB-500 the Same Thing as Thymosin Beta-4?

No. TB-500 is a much shorter fragment, just seven amino acids, corresponding to one specific functional region of the larger 43-amino-acid Thymosin Beta-4 protein.

What Has TB-500 Been Studied For?

Research specifically on this fragment has focused on wound repair in delayed-healing animal models and blood vessel formation. The broader parent protein has a wider research base that this fragment builds on.

How Does TB-500 Work?

Research points to it binding actin, the protein that helps cells move and change shape, which supports both cell migration during tissue repair and the formation of new blood vessels.

Has TB-500 Been Tested in Humans?

No published human clinical trial data exists for this specific fragment. The full-length Thymosin Beta-4 protein has been studied in human trials for other applications, but that research doesn't directly transfer to this shortened version.

Sources and Research

  1. Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24.
  2. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105.
  3. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368.
  4. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
  5. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).

Related Reading

For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.